Please use this identifier to cite or link to this item:
Title: Agreement between pharmaceutical claims data and patient-reported medication use after stroke.
Austin Authors: Dalli, Lachlan L;Andrew, Nadine E;Cadilhac, Dominique A;Kim, Joosup;Sanfilippo, Frank M;Kilkenny, Monique F
Affiliation: Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia
Peninsula Clinical School, Central Clinical School, Monash University, Frankston, VIC, Australia
School of Population and Global Health, The University of Western Australia, Perth, WA, Australia
The Florey Institute of Neuroscience and Mental Health
Issue Date: 11-Aug-2021 2021-06-24
Publication information: The International Journal of Pharmacy Practice 2021; 29(4): 397-399
Abstract: To assess the agreement between pharmaceutical claims data and patient-reported medication use after stroke. Claims data from the Pharmaceutical Benefits Scheme were used to estimate medication use for a subset of participants registered in the Australian Stroke Clinical Registry in 2016. Estimates on medication use were validated against patient-reported responses (considered the reference standard). For antihypertensive and lipid-lowering medications, the sensitivity of claims data was excellent (85-87%) and the specificity was good (73-78%). Whereas for antithrombotic medications, sensitivity was modest (61%), but specificity was excellent (85%). Pharmaceutical claims data can be used to infer medication use after stroke with mostly good to excellent sensitivity and specificity compared with the patient report.
DOI: 10.1093/ijpp/riab032
ORCID: 0000-0003-1449-9132
PubMed URL: 34165141
Type: Journal Article
Subjects: administrative claims
healthcare validation study
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.